Insider trading

Period: 120 months Stock: WVE Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

41 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

41 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

41 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

41 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
41 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
41 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

41 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
26 Feb 2026
Francis Chris See Remarks
Sold on a plan 2×
$499.59K 33,194 at 15.05
34.9%
Planned (10b5-1)
9 Feb 2026
Vargeese Chandra See Remarks
Sold at will
$43.42K 3,228 at 13.45
0.8%
Not planned
9 Feb 2026
Francis Chris See Remarks
Sold at will
$25.33K 1,883 at 13.45
3.0%
Not planned
2 Jan 2026
Francis Chris See Remarks
Sold on a plan 2×
$150.26K 9,375 at 16.03
27.3%
Planned (10b5-1)
8 Dec 2025
Francis Chris See Remarks
Sold on a plan 9×
$6.43M 441,031 at 14.57
94.6%
Sold half or more
8 Nov 2024
Francis Chris See Remarks
Sold on a plan
$576.00K 36,000 at 16.00
100%
Sold half or more
16 Oct 2024
Francis Chris See Remarks
Sold on a plan 4×
$2.86M 208,836 at 13.67
100%
Sold half or more
16 Feb 2023
Francis Chris See Remarks
Sold, plan not stated
$41.34K 10,258 at 4.03
11.4%
16 Feb 2023
Vargeese Chandra See Remarks
Sold, plan not stated
$41.30K 10,249 at 4.03
8.8%
5 May 2022
Vargeese Chandra See Remarks
Sold, plan not stated
$28.75K 16,714 at 1.72
13.1%
5 May 2022
Panzara Michael A. See Remarks
Sold, plan not stated
$28.75K 16,714 at 1.72
13.3%
5 May 2022
Francis Chris See Remarks
Sold, plan not stated
$18.69K 10,867 at 1.72
10.8%
16 Feb 2022
Vargeese Chandra Chief Technology Officer
Sold, plan not stated
$24.60K 10,603 at 2.32
12.0%
16 Feb 2022
Panzara Michael A. See Remarks
Sold, plan not stated
$24.49K 10,603 at 2.31
12.3%
16 Feb 2022
Francis Chris See Remarks
Sold, plan not stated
$23.38K 10,123 at 2.31
12.9%
16 Feb 2021
Vargeese Chandra Chief Technology Officer
Sold, plan not stated
$33.24K 3,145 at 10.57
3.6%
16 Feb 2021
Panzara Michael A. See Remarks
Sold, plan not stated
$30.96K 2,929 at 10.57
3.3%
16 Feb 2021
Francis Chris See Remarks
Sold, plan not stated
$28.52K 2,698 at 10.57
3.3%
18 Feb 2020
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$25.03K 3,188 at 7.85
7.9%
18 Feb 2020
Panzara Michael A. Chief Medical Officer
Sold, plan not stated
$23.40K 2,981 at 7.85
7.0%
18 Feb 2020
Francis Chris See Remarks
Sold, plan not stated
$21.26K 2,708 at 7.85
8.0%
3 Dec 2019
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$210.00K 6,000 at 35.00
13.0%
5 Jul 2019
Panzara Michael A. Chief Medical Officer
Sold, plan not stated 2×
$82.37K 3,058 at 26.94
6.7%
11 Mar 2019
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$336.00K 7,000 at 48.00
13.4%
19 Feb 2019
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$75.71K 2,055 at 36.84
7.5%
19 Feb 2019
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$67.67K 1,837 at 36.84
4.7%
19 Feb 2019
Francis Chris See Remarks
Sold, plan not stated
$62.96K 1,709 at 36.84
7.7%
25 Sep 2018
Francis Chris See Remarks
Sold, plan not stated
$590.41K 10,543 at 56.00
32.3%
24 Sep 2018
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$165.00K 3,000 at 55.00
9.9%
24 Sep 2018
Francis Chris See Remarks
Sold, plan not stated
$57.79K 1,032 at 56.00
4.5%
9 Jul 2018
Francis Chris See Remarks
Sold, plan not stated 2×
$913.05K 24,496 at 37.27
52.6%
Sold half or more
1 Jun 2018
Francis Chris See Remarks
Sold, plan not stated
$1.18M 24,496 at 48.00
52.6%
Sold half or more
30 May 2018
Francis Chris See Remarks
Sold, plan not stated
$1.11M 24,496 at 45.50
52.6%
Sold half or more
20 Feb 2018
Francis Chris See Remarks
Sold, plan not stated
$643.65K 11,504 at 55.95
34.3%
16 Feb 2018
Francis Chris See Remarks
Sold, plan not stated 2×
$555.11K 10,135 at 54.77
31.5%
16 Feb 2018
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$26.62K 511 at 52.10
1.3%
15 Feb 2018
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$937.50K 18,750 at 50.00
32.1%
15 Feb 2018
Vargeese Chandra See Remarks
Sold, plan not stated
$100.00K 2,000 at 50.00
6.8%
23 Jan 2018
Vargeese Chandra See Remarks
Sold, plan not stated
$80.00K 2,000 at 40.00
16.9%
22 Nov 2017
Vargeese Chandra See Remarks
Sold, plan not stated
$52.50K 1,500 at 35.00
100%
Sold half or more
12 Jul 2017
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$123.62K 7,414 at 16.67
32.6%
Showing 1–41 of 41.